These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 39125897)

  • 21. Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease.
    Chen Z; Jiang P; Su D; Zhao Y; Zhang M
    Cytokine Growth Factor Rev; 2024 Oct; 79():1-15. PubMed ID: 39179485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
    Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
    Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective JAK inhibitors in development for rheumatoid arthritis.
    Norman P
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1067-77. PubMed ID: 24818516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.
    McInnes IB; Szekanecz Z; McGonagle D; Maksymowych WP; Pfeil A; Lippe R; Song IH; Lertratanakul A; Sornasse T; Biljan A; Deodhar A
    Rheumatology (Oxford); 2022 May; 61(5):1783-1794. PubMed ID: 34668515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The JAK inhibitor baricitinib inhibits oncostatin M induction of proinflammatory mediators in ex-vivo synovial derived cells.
    Weston S; Macdonald JL; Williams LM; Roussou E; Kang NV; Kiriakidis S; Taylor PC
    Clin Exp Rheumatol; 2022 Sep; 40(9):1620-1628. PubMed ID: 34665696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis.
    Srivastava S; Rasool M
    Life Sci; 2022 Jun; 298():120516. PubMed ID: 35367240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
    Roskoski R
    Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small molecule drug discovery targeting the JAK-STAT pathway.
    Lv Y; Mi P; Babon JJ; Fan G; Qi J; Cao L; Lang J; Zhang J; Wang F; Kobe B
    Pharmacol Res; 2024 Jun; 204():107217. PubMed ID: 38777110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
    Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
    Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.
    Taylor PC; Choy E; Baraliakos X; Szekanecz Z; Xavier RM; Isaacs JD; Strengholt S; Parmentier JM; Lippe R; Tanaka Y
    Rheumatology (Oxford); 2024 Feb; 63(2):298-308. PubMed ID: 37624925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.
    Lee YH; Song GG
    Pharmacology; 2023; 108(6):589-598. PubMed ID: 37591216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
    Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
    Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors.
    Kitanaga Y; Imamura E; Nakahara Y; Fukahori H; Fujii Y; Kubo S; Nakayamada S; Tanaka Y
    Rheumatology (Oxford); 2020 Aug; 59(8):1957-1968. PubMed ID: 31764973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum.
    El Jammal T; Gerfaud-Valentin M; Sève P; Jamilloux Y
    Joint Bone Spine; 2020 Mar; 87(2):119-129. PubMed ID: 31521793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
    Veale DJ; McGonagle D; McInnes IB; Krueger JG; Ritchlin CT; Elewaut D; Kanik KS; Hendrikx T; Berstein G; Hodge J; Telliez JB
    Rheumatology (Oxford); 2019 Feb; 58(2):197-205. PubMed ID: 29618084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [JAK inhibition in the treatment of inflammatory rheumatic diseases].
    Šenolt L
    Vnitr Lek; 2023; 69(3):181-188. PubMed ID: 37468313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JAK/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis.
    Crispino N; Ciccia F
    Clin Exp Rheumatol; 2021; 39(3):668-675. PubMed ID: 33200731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Janus kinase inhibitors in autoimmune bullous diseases.
    Huang D; Zhang Y; Kong L; Lu J; Shi Y
    Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors.
    Yarilina A; Xu K; Chan C; Ivashkiv LB
    Arthritis Rheum; 2012 Dec; 64(12):3856-66. PubMed ID: 22941906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes.
    Migita K; Komori A; Torigoshi T; Maeda Y; Izumi Y; Jiuchi Y; Miyashita T; Nakamura M; Motokawa S; Ishibashi H
    Arthritis Res Ther; 2011 May; 13(3):R72. PubMed ID: 21548952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.